TB Activist Toolkits
TAG's TB Activist Toolkits provide fundamental information about tuberculosis (TB) in order to strengthen global advocacy and understanding of the latest innovations, evidence, and guidance around TB and TB/HIV. These toolkits cover important base knowledge on TB and TB/HIV, as well…
Treatment Action Group Joins Collective Call Denouncing the Trump Administration’s Dangerous Finalized Anti-Immigrant Rule
Statement from Treatment Action Group on U.S. FDA Approval of Pretomanid
The Tuberculosis Vaccines Pipeline
June 2013 Where are we going, where have we been? By Mike Frick Since the 2012 Pipeline Report, results from phase II trials and advances in preclinical development have brought the pipeline for new TB vaccines into sharper focus, even…
The Tuberculosis Treatment Pipeline
June 2013 Better than Ever Is Not Good Enough By Erica Lessem NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2013. Introduction In December 2012, tuberculosis (TB) treatment reached a historic…
The Tuberculosis Diagnostics Pipeline
June 2013 By Colleen Daniels Currently, smear microscopy and mycobacterial culture are the most widely used diagnostic tests, but microscopy, though relatively fast, is too inaccurate—missing over half of cases1—while culture is accurate but slow, taking from two to eight…
The Tuberculosis Vaccines Pipeline
July 2014 Back to basic science By Mike Frick The last year in tuberculosis (TB) vaccine research has demonstrated how setbacks can sometimes produce the potential for unexpected progress. Dominant hypotheses have yielded to new investigative directions, and unresolved questions…
Playing Catch-Up: The Pediatric Tuberculosis Treatment Pipeline
July 2014 By Lindsay McKenna Introduction While the pediatric HIV drug pipeline has seen increased activity in recent years, the same cannot be said for pediatric TB. Adult-pediatric approval gaps remain an issue in HIV drug development, especially for children…
Tuberculosis Drug Development Hobbles Forward
July 2014 By Erica Lessem Introduction After forty years without new approved drug classes, tuberculosis (TB) treatment has recently advanced with the approval of two new compounds to treat multidrug-resistant TB (MDR-TB): delamanid and bedaquiline.1,2,3 Yet with limited access to…